Early predictors of glucocorticosteroid treatment failur severe attacks of ulcerative colitis

European Journal of Gastroenterology and Hepatology 10, 831-836

DOI: 10.1097/00042737-199810000-00003

Citation Report

#	Article	lF	CITATIONS
1	Prediction of Treatment Refractoriness in Ulcerative Colitis and CrohnÊ⅓s Diseaseâ€"Do We Have Reliable Markers?. Inflammatory Bowel Diseases, 2000, 6, 123-131.	0.9	20
2	Clinical Evaluation and Management of Acute Severe Colitis. Inflammatory Bowel Diseases, 2000, 6, 214-227.	0.9	29
3	Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2000, 14, 273-279.	1.9	120
4	Biopsy Pathology Predicts Patients with Ulcerative Colitis Subsequently Requiring Surgery. Scandinavian Journal of Gastroenterology, 2002, 37, 200-205.	0.6	54
5	Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index. Journal of Gastroenterology, 2002, 37, 29-34.	2.3	66
6	Medical treatment of severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2002, 16, 7-12.	1.9	38
7	Management of acute severe colitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 89-103.	1.0	14
8	Validity of Simple Mucosal Biopsy Criteria Combined with Endoscopy Predicting Patients with Ulcerative Colitis Ultimately Requiring Surgery: A Multicenter Study. Scandinavian Journal of Gastroenterology, 2003, 38, 594-598.	0.6	10
10	Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Alimentary Pharmacology and Therapeutics, 2004, 19, 1079-1087.	1.9	240
11	The management of mild to severe acute ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2004, 20, 88-92.	1.9	30
13	Predicting outcome in severe ulcerative colitis. Digestive and Liver Disease, 2004, , .	0.4	0
14	Medical therapy for ulcerative colitis 2004. Gastroenterology, 2004, 126, 1582-1592.	0.6	157
15	Conservative approach to severe ulcerative colitis. Digestive and Liver Disease, 2004, 36, 4-6.	0.4	1
16	Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Digestive and Liver Disease, 2004, 36, 461-466.	0.4	55
17	Predicting outcome in severe ulcerative colitis. Digestive and Liver Disease, 2004, 36, 448-449.	0.4	18
18	Review article: how and when to use ciclosporin in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 22, 907-916.	1.9	48
19	Does Daily Fecal Volume Predict the Clinical Outcome of the Acute Flare of Extensive Ulcerative Colitis in Terms of Need for Acute Colectomy?. Inflammatory Bowel Diseases, 2005, 11, 418-419.	0.9	0
20	Desensitization Treatment of An Aspirin- and Mesalamine-Sensitive Patient With Crohn $\hat{E}^{1}\!\!/4$ s Disease. Inflammatory Bowel Diseases, 2005, 11, 417-419.	0.9	9

#	Article	IF	Citations
22	Management of acute severe colitis. British Medical Bulletin, 2005, 75-76, 131-144.	2.7	73
23	Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study. Gastroenterology, 2005, 128, 1805-1811.	0.6	1,065
24	Treatment of Crohn's Disease: The "Long―of lt. Gastroenterology, 2005, 128, 2164-2166.	0.6	6
25	Infliximab for Ulcerative Colitis: Finally Some Answers. Gastroenterology, 2005, 128, 2161-2164.	0.6	30
27	Predicting Outcome in Severe UC., 0,, 153-155.		0
28	Inflammatory bowel disease: the view of the surgeon. Colorectal Disease, 2006, 8, 10-14.	0.7	40
29	Review article: saving the colon in severe colitis – the case for medical therapy. Alimentary Pharmacology and Therapeutics, 2006, 24, 68-73.	1.9	17
30	Review article: interactions between genotype and response to therapy in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2006, 24, 1403-1412.	1.9	13
31	Predictors of Clinical Response to Systemic Steroids in Active Ulcerative Colitis. Digestive Diseases and Sciences, 2006, 51, 1434-1438.	1.1	27
32	Risk Factors and Indications for Colectomy in Ulcerative Colitis Patients are Different According to Patient's Clinical Background. Diseases of the Colon and Rectum, 2006, 49, 1307-1315.	0.7	29
33	Current management of severe ulcerative colitis. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 92-101.	1.7	51
34	Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression. Clinical Gastroenterology and Hepatology, 2007, 5, 103-110.	2.4	544
35	A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis. Gastroenterology, 2007, 132, 763-786.	0.6	917
36	Glucocorticoid Resistance in Inflammatory Diseases. NeuroImmune Biology, 2007, , 349-358.	0.2	1
37	Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial. American Journal of Gastroenterology, 2007, 102, 601-608.	0.2	95
39	American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006. Gastroenterology, 2007, 133, 312-339.	0.6	197
40	Development, Validation, and Evaluation of a Pediatric Ulcerative Colitis Activity Index: A Prospective Multicenter Study. Gastroenterology, 2007, 133, 423-432.	0.6	847
41	Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies. Alimentary Pharmacology and Therapeutics, 2007, 25, 111-122.	1.9	55

#	Article	IF	CITATIONS
42	Review article: the management of steroid dependency in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2007, 26, 779-794.	1.9	55
43	A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2007, 26, 411-419.	1.9	132
45	Acute and chronic megacolon. Current Treatment Options in Gastroenterology, 2007, 10, 237-247.	0.3	16
47	Biological agents for ulcerative colitis: Hypes and hopes. Medicinal Research Reviews, 2008, 28, 201-218.	5.0	24
48	Steroid-refractory ulcerative colitis: Predictive factors of response to cyclosporine and validation in an independent cohort. Inflammatory Bowel Diseases, 2008, 14, 347-352.	0.9	48
49	US estimates of hospitalized pediatric patients with ulcerative colitis: Implications for multicenter clinical studies. Inflammatory Bowel Diseases, 2008, 14, 1253-1258.	0.9	4
50	How to judge the response to treatment in ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S222-S223.	0.9	2
51	In the case of nonresponse to steroids, what is the second level of treatment in ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S226-S227.	0.9	0
52	Predictive factors associated with immunosuppressive agent use in ulcerative colitis: a case–control study. Alimentary Pharmacology and Therapeutics, 2008, 28, 606-613.	1.9	22
53	The Management of Acute Severe Colitis: ACPGBI Position Statement. Colorectal Disease, 2008, 10, 8-29.	0.7	45
54	Steroid-Refractory Severe Ulcerative Colitis. Drugs, 2008, 68, 1157-1167.	4.9	27
55	European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohn's and Colitis, 2008, 2, 1-23.	0.6	470
56	European evidence-based Consensus on the management of ulcerative colitis: Current management. Journal of Crohn's and Colitis, 2008, 2, 24-62.	0.6	473
57	Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis. American Journal of Gastroenterology, 2008, 103, 637-642.	0.2	97
58	Severe ulcerative colitis: present medical treatment strategies. Expert Opinion on Pharmacotherapy, 2008, 9, 447-457.	0.9	9
59	Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut, 2008, 57, 331-338.	6.1	153
60	Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 357-370.	1.4	16
61	Pathogenesis and Clinical Practice in Gastroenterology. , 2008, , .		0

#	Article	IF	Citations
62	In the case of nonresponse to steroids, what is the second level of treatment in ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S226-S227.	0.9	O
63	How to judge the response to treatment in ulcerative colitis?. Inflammatory Bowel Diseases, 2008, 14, S222-S223.	0.9	0
64	Timing of surgery in Crohnâ \in TM s disease: A key issue in the management. World Journal of Gastroenterology, 2008, 14, 5532.	1.4	53
65	Severe Acute Ulcerative Colitis: The Pediatric Perspective. Digestive Diseases, 2009, 27, 322-326.	0.8	18
66	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 176-181.	0.9	67
67	Treatment of choice for acute severe steroid-refractory ulcerative colitis is Remicade. Inflammatory Bowel Diseases, 2009, 15, 143-145.	0.9	10
68	Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis. American Journal of Gastroenterology, 2009, 104, 673-678.	0.2	143
69	Surgery in Ulcerative Colitis: Indication and Timing. Digestive Diseases, 2009, 27, 335-340.	0.8	81
70	Treatment of steroid-naive ulcerative colitis. Expert Opinion on Pharmacotherapy, 2009, 10, 1449-1460.	0.9	7
71	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 729-752.	1.0	6
72	Impact of Narcotic Use on the Requirement for Colectomy in Inpatients With Ulcerative Colitis. Diseases of the Colon and Rectum, 2010, 53, 1295-1300.	0.7	9
73	Histopathology Predictors of Medically Refractory Ulcerative Colitis. Diseases of the Colon and Rectum, 2010, 53, 1280-1286.	0.7	16
74	A fulminant colitis index greater or equal to 8Âis not predictive of colectomy risk in infliximab-treated moderate-to-severe ulcerative colitis attacks. Gastroenterologie Clinique Et Biologique, 2010, 34, 612-617.	0.9	2
75	Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents. Inflammatory Bowel Diseases, 2010, 16, S1-S11.	0.9	16
76	Review article: the optimal medical management of acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2010, 32, 615-627.	1.9	33
77	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3â€year followâ€up of the Swedishâ€Danish controlled infliximab study. Alimentary Pharmacology and Therapeutics, 2010, 32, 984-989.	1.9	164
78	Gene Expression Changes Associated with Resistance to Intravenous Corticosteroid Therapy in Children with Severe Ulcerative Colitis. PLoS ONE, 2010, 5, e13085.	1.1	37
79	What Determines the Later Clinical Course of Patients Who Do Not Undergo Colectomy at the First Attack A Japanese Cohort Study on Ulcerative Colitis. Digestion, 2010, 81, 104-112.	1.2	18

#	Article	IF	CITATIONS
80	Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut, 2010, 59, 1207-1212.	6.1	114
81	Management of Acute Colitis and Toxic Megacolon. Clinics in Colon and Rectal Surgery, 2010, 23, 274-284.	0.5	32
82	Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. Journal of Crohn's and Colitis, 2010, 4, 398-404.	0.6	41
83	Severe Pediatric Ulcerative Colitis: A Prospective Multicenter Study of Outcomes and Predictors of Response. Gastroenterology, 2010, 138, 2282-2291.	0.6	233
84	Novel Diagnostic and Prognostic Modalities in Inflammatory Bowel Disease. Medical Clinics of North America, 2010, 94, 155-178.	1.1	4
85	C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. Journal of Crohn's and Colitis, 2011, 5, 423-429.	0.6	63
86	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Diseasea~†. Digestive and Liver Disease, 2011, 43, 1-20.	0.4	125
87	Consensus for Managing Acute Severe Ulcerative Colitis in Children: A Systematic Review and Joint Statement From ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. American Journal of Gastroenterology, 2011, 106, 574-588.	0.2	176
88	Guidelines for the management of inflammatory bowel disease in adults. Gut, 2011, 60, 571-607.	6.1	1,127
89	Lessons to Learn from Crohn's Disease Clinical Trials: Implications for Ulcerative Colitis. Current Drug Targets, 2011, 12, 1467-1477.	1.0	0
90	Surgical Approach to Ulcerative Colitis: When is the Best Timing after Medical Treatment?. Current Drug Targets, 2011, 12, 1462-1466.	1.0	8
91	Clinical outcomes and factors for response prediction after the first course of corticosteroid therapy in patients with active ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1114-1122.	1.4	18
92	Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitisâ€"a preliminary study. European Radiology, 2011, 21, 366-377.	2.3	26
93	Acute severe ulcerative colitis in children: A systematic review. Inflammatory Bowel Diseases, 2011, 17, 440-449.	0.9	90
94	Decision tree for early introduction of rescue therapy in active ulcerative colitis treated with steroids. Inflammatory Bowel Diseases, 2011, 17, 2497-2502.	0.9	25
96	Acute Severe Colitis: Infliximab and/or Cyclosporine?. Current Drug Targets, 2011, 12, 1448-1453.	1.0	4
97	Acute severe ulcerative colitis: timing is everything. Postgraduate Medical Journal, 2011, 87, 215-222.	0.9	12
98	Predicting the need for colectomy in severe ulcerative colitis: a critical appraisal of clinical parameters and currently available biomarkers. Gut, 2011, 60, 3-9.	6.1	93

#	ARTICLE	IF	CITATIONS
99	Impact of gastroenterologist care on health outcomes of hospitalised ulcerative colitis patients. Gut, 2012, 61, 1410-1416.	6.1	39
100	Calcineurin Inhibitors or Anti-TNF-α Agents in Severe Ulcerative Colitis: Available Options and Limitations. Zeitschrift Fur Gastroenterologie, 2012, 50, 396-406.	0.2	3
101	Glucocorticoid sensitivity in inflammatory bowel disease. Annals of Medicine, 2012, 44, 578-587.	1.5	19
102	Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Alimentary Pharmacology and Therapeutics, 2012, 36, 744-754.	1.9	19
103	Clinical Predictors of Aggressive/Disabling Disease: Ulcerative Colitis and Crohn Disease. Gastroenterology Clinics of North America, 2012, 41, 443-462.	1.0	28
104	Strategies for the Care of Adults Hospitalized for Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2012, 10, 1315-1325.e4.	2.4	54
105	Commentary: predicting response to ciclosporin in acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2012, 36, 1095-1096.	1.9	1
106	Commentary: predicting response to ciclosporin in acute severe ulcerative colitis – authors' reply. Alimentary Pharmacology and Therapeutics, 2012, 36, 1096-1097.	1.9	O
107	Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. Journal of Crohn's and Colitis, 2012, 6, 750-755.	0.6	28
108	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management. Journal of Crohn's and Colitis, 2012, 6, 991-1030.	0.6	1,106
109	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. Journal of Crohn's and Colitis, 2012, 6, 965-990.	0.6	715
110	Treatment of Hospitalized Adult Patients With Severe Ulcerative Colitis: Toronto Consensus Statements. American Journal of Gastroenterology, 2012, 107, 179-194.	0.2	142
111	Surgical treatment of ulcerative colitis in the biologic therapy era. World Journal of Gastroenterology, 2012, 18, 1861.	1.4	42
113	Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study. Inflammatory Bowel Diseases, 2012, 18, 212-218.	0.9	54
114	Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. Alimentary Pharmacology and Therapeutics, 2013, 38, 377-387.	1.9	73
115	Interleukin-6 is associated with steroid resistance and reflects disease activity in severe pediatric ulcerative colitis. Journal of Crohn's and Colitis, 2013, 7, 916-922.	0.6	43
116	Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD. Journal of Crohn's and Colitis, 2013, 7, 730-735.	0.6	95
117	Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Alimentary Pharmacology and Therapeutics, 2013, 38, 294-302.	1.9	82

#	ARTICLE	IF	CITATIONS
118	Management of acute severe ulcerative colitis. World Journal of Gastrointestinal Pathophysiology, 2014, 5, 579.	0.5	40
119	Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis. Scandinavian Journal of Gastroenterology, 2014, 49, 424-433.	0.6	7
121	Faecal analysis and plasma complement factor 3c levels at admission for an acute attack of ulcerative colitis are predictive of the need for colectomy. European Journal of Gastroenterology and Hepatology, 2014, 26, 295-300.	0.8	2
122	In vitro sensitivity assays and clinical response to glucocorticoids in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 1539-1547.	0.6	8
123	The Hospitalized Adult with Severe Ulcerative Colitis. Hospital Medicine Clinics, 2014, 3, 531-541.	0.2	0
125	An Update on Anti-TNF Agents in Ulcerative Colitis. Gastroenterology Clinics of North America, 2014, 43, 479-494.	1.0	17
126	Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy. Colorectal Disease, 2014, 16, O420-30.	0.7	81
127	Surgical and medical treatment in patients with acute severe ulcerative colitis. Journal of Digestive Diseases, 2015, 16, 558-567.	0.7	21
128	Predicting outcomes in acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2015, 9, 405-415.	1.4	12
129	Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort Studies. Journal of Crohn's and Colitis, 2015, 9, 156-163.	0.6	76
130	Medical Therapy of Active Ulcerative Colitis. Visceral Medicine, 2015, 31, 236-245.	0.5	6
132	Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2015, 13, 635-642.	2.4	45
133	Update on medical and surgical options for patients with acute severe ulcerative colitis: What is new?. World Journal of Gastrointestinal Surgery, 2016, 8, 598.	0.8	17
134	Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 1293-1299.	1.9	72
135	Review article: the practical management of acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2016, 43, 482-513.	1.9	72
136	Acute severe ulcerative colitis: from pathophysiology to clinical management. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 654-664.	8.2	129
137	Review article: acute severe ulcerative colitis – evidenceâ€based consensus statements. Alimentary Pharmacology and Therapeutics, 2016, 44, 127-144.	1.9	63
138	Improved outcome of acute severe ulcerative colitis while using early predictors of corticosteroid failure and rescue therapies. Digestive and Liver Disease, 2016, 48, 608-612.	0.4	17

#	Article	IF	CITATIONS
139	Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 617-630.	1.9	68
140	Short-Term Clinical Response to Corticosteroids Can Predict Long-Term Natural History of Ulcerative Colitis: Prospective Study Experience. Digestive Diseases and Sciences, 2017, 62, 1025-1034.	1.1	10
141	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	0.6	1,324
142	Fecal calprotectin as an alternative to ulcerative colitis endoscopic index of severity to predict the response to corticosteroids of acute severe ulcerative colitis: A prospective observational study. Digestive and Liver Disease, 2017, 49, 984-990.	0.4	20
143	Faecal Calprotectin and UCEIS Predict Short-term Outcomes in Acute Severe Colitis: Prospective Cohort Study. Journal of Crohn's and Colitis, 2017, 11, 1309-1316.	0.6	46
144	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis, 2017, 11, 769-784.	0.6	876
145	Value of upper endoscopic biopsies in predicting medical refractoriness in pediatric patients with ulcerative colitis. Human Pathology, 2017, 66, 167-176.	1.1	9
146	Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intestinal Research, 2017, 15, 266.	1.0	34
147	Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study. Journal of Crohn's and Colitis, 2018, 12, 289-297.	0.6	39
148	Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis. Gastroenterology Report, 2018, 6, 38-44.	0.6	78
149	Acute severe ulcerative colitis: latest evidence and therapeutic implications. Therapeutic Advances in Chronic Disease, 2018, 9, 65-72.	1.1	50
150	CRP/Albumin Ratio. Journal of Clinical Gastroenterology, 2018, 52, e48-e52.	1.1	64
151	The effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481880978.	1.4	6
152	The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Disease, 2018, 20, 3-117.	0.7	52
154	Management of Paediatric Ulcerative Colitis, Part 2. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 292-310.	0.9	156
155	Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 56-66.	0.9	11
156	Surgery in ulcerative colitis: When? How?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 32-33, 71-78.	1.0	56
157	Outcomes and prediction of corticosteroid therapy after successive courses of ulcerative colitis treatments. Expert Review of Gastroenterology and Hepatology, 2018, 12, 733-741.	1.4	5

#	Article	IF	CITATIONS
158	Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 541-546.	0.9	13
159	The Writing Is on the Wall: The Utility of Mural Stratification for Risk Stratification of Hospitalized Patients with Severe Ulcerative Colitis. Digestive Diseases and Sciences, 2019, 64, 2072-2074.	1.1	2
160	An approach to acute severe ulcerative colitis. Expert Review of Gastroenterology and Hepatology, 2019, 13, 943-955.	1.4	10
161	Infliximab clinically treating ulcerative colitis: A systematic review and meta-analysis. Pharmacological Research, 2019, 148, 104455.	3.1	30
162	British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut, 2019, 68, s1-s106.	6.1	1,353
163	Chronic Active Ulcerative Colitis. , 2019, , 131-140.		0
164	Early Response to Corticosteroid and Baseline C-Reactive Protein Predicts Outcomes in Children with Moderate to Severe Ulcerative Colitis. Digestive Diseases and Sciences, 2019, 64, 1929-1937.	1.1	6
165	A comparison of long-term healthcare utilization and costs in patients with acute severe ulcerative colitis receiving infliximab <i>versus</i> early colectomy. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231982559.	1.1	6
166	Management of Acute Severe Colitis in the Era of Biologicals and Small Molecules. Journal of Clinical Medicine, 2019, 8, 2169.	1.0	12
167	Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis. Digestive Diseases and Sciences, 2019, 64, 3263-3273.	1.1	17
168	25 Ulcerative Colitis., 2019, , .		0
169	Optimal management of acute severe ulcerative colitis. Postgraduate Medical Journal, 2019, 95, 32-40.	0.9	15
170	Updated S3-Guideline Ulcerative Colitis. German Society for Digestive and Metabolic Diseases (DGVS). Zeitschrift Fur Gastroenterologie, 2019, 57, 162-241.	0.2	41
171	Shortâ€term colectomy is avoided in over half of regional patients failing medical therapy for acute severe ulcerative colitis with coâ€ordinated transfer and tertiary care. Internal Medicine Journal, 2020, 50, 823-829.	0.5	3
172	Ulcerative Colitis: Current and Emerging Treatment Strategies. Journal of Clinical Medicine, 2020, 9, 94.	1.0	53
173	Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clinical Gastroenterology and Hepatology, 2020, 18, 1346-1355.	2.4	21
174	Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterology Clinics of North America, 2020, 49, 671-688.	1.0	49
175	Corticosteroid exposure prior to admission and predicting need for rescue therapy in acute severe ulcerative colitis. Internal Medicine Journal, 2022, 52, 828-833.	0.5	2

#	Article	IF	Citations
176	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1602-1610.e1.	2.4	26
177	Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome. Scandinavian Journal of Gastroenterology, 2020, 55, 555-559.	0.6	3
178	Longâ€term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Alimentary Pharmacology and Therapeutics, 2020, 51, 1096-1104.	1.9	19
179	Predicting Outcome in Acute Severe Colitisâ€"Controversies in Clinical Practice in 2021. Journal of Crohn's and Colitis, 2021, 15, 1211-1221.	0.6	17
180	How to manage: acute severe colitis. Frontline Gastroenterology, 2022, 13, 64-72.	0.9	5
181	The effects of flaxseed supplementation on gene expression and inflammation in ulcerative colitis patients: An openâ€labelled randomised controlled trial. International Journal of Clinical Practice, 2021, 75, e14035.	0.8	6
182	A Simple Emergency Department-Based Score Predicts Complex Hospitalization in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2022, 67, 629-638.	1.1	4
183	Low serum albumin at admission is a predictor of early colectomy in patients with moderate to severe ulcerative colitis. JGH Open, 2021, 5, 377-381.	0.7	10
184	Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Internal and Emergency Medicine, 2021, 16, 1433-1442.	1.0	5
185	Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy. Intestinal Research, 2022, 20, 101-113.	1.0	21
186	A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2762-2768.	1.4	3
187	The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis. Scandinavian Journal of Gastroenterology, 2021, 56, 1049-1055.	0.6	2
188	The Role of Biomarkers in Surgery for Ulcerative Colitis: A Review. Journal of Clinical Medicine, 2021, 10, 3362.	1.0	6
189	Anti-proteinase 3 antineutrophil cytoplasmic antibody reflects disease activity and predicts the response to steroid therapy in ulcerative colitis. BMC Gastroenterology, 2021, 21, 325.	0.8	8
190	Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease-do we have reliable markers?. Inflammatory Bowel Diseases, 0, 6, 123-131.	0.9	4
191	Clinical evaluation and management of acute severe colitis. Inflammatory Bowel Diseases, 0, 6, 214-227.	0.9	3
195	Glucocorticoid unresponsiveness in severe ulcerative colitis. Gut, 1999, 45, 324-325.	6.1	3
196	Short-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative Colitis. Ulcers, 2011, 2011, 1-7.	1.0	5

#	Article	IF	CITATIONS
197	PROJECT: CLINICAL GUIDELINES FOR THE DIAGNOSTICS AND TREATMENT OF ULCERATIVE COLITIS. Koloproktologia, 2019, 18, 7-36.	0.1	39
198	Severe ulcerative colitis: At what point should we define resistance to steroids?. World Journal of Gastroenterology, 2008, 14, 5504.	1.4	7
199	Role of surgery in severe ulcerative colitis in the era of medical rescue therapy. World Journal of Gastroenterology, 2012, 18, 3833.	1.4	33
200	Corticosteroid therapy in ulcerative colitis: Clinical response and predictors. World Journal of Gastroenterology, 2015, 21, 3005.	1.4	22
201	First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World Journal of Gastroenterology, 2020, 26, 6710-6769.	1.4	12
202	Correlation between fecal calprotectin, ulcerative colitis endoscopic index of severity and clinical outcome in patients with acute severe colitis. Experimental and Therapeutic Medicine, 2020, 20, 1498-1504.	0.8	10
203	Guidelines for the Management of Ulcerative Colitis. Intestinal Research, 2012, 10, 1.	1.0	12
204	Predictors of Steroid Treatment Failure and Validation of Previous Models for Severe Attacks of Ulcerative Colitis. Intestinal Research, 2012, 10, 251.	1.0	1
205	High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis. Intestinal Research, 2021, 19, 438-447.	1.0	9
206	High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. , 2020, 24, 1-10.		13
207	Medical Treatment of Ulcerative Colitis. , 2006, , 229-238.		0
208	Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis. American Journal of Gastroenterology, 2009, 104, 673-678.	0.2	89
209	Biologic Therapies For Inflammatory Bowel Disease. , 2009, , .		0
211	When Is Surgery Indicated in Ulcerative Colitis?. , 2011, , 42-47.		0
212	Conventional Medical Management of Ulcerative Colitis: Corticosteroids. , 2012, , 467-472.		0
213	Oral and Parenteral Corticosteroid Therapy in Ulcerative Colitis. , 2014, , 111-119.		0
218	Standard therapy for ulcerative colitis and Crohn's disease: the ECCO guidelines. , 2008, , 76-89.		0
219	Promising effect of infliximab on the extent of involvement in ulcerative colitis. Journal of Research in Medical Sciences, 2011, 16, 6-15.	0.4	40

#	Article	IF	Citations
220	Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. Journal of Clinical Medicine, 2021, 10, 5413.	1.0	1
221	Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab. Journal of Clinical Medicine, 2022, 11, 1679.	1.0	7
222	A Clinical Predictive Model for One-year Colectomy in Adults Hospitalized for Severe Ulcerative Colitis. Crohn's & Colitis 360, 2022, 4, .	0.5	2
225	Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian Journal of Gastroenterology, 2022, 41, 273-283.	0.7	6
228	Development and validation of novel models for the prediction of intravenous corticosteroid resistance in acute severe ulcerative colitis using logistic regression and machine learning. Gastroenterology Report, 2022, 10 , .	0.6	2
229	Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response. Gut, 2023, 72, 433-442.	6.1	16
230	Infliximab and Plant-Based Diet as First-Line Therapy Followed by Corticosteroid Therapy for Severe Ulcerative Colitis: A Case Report. Gastrointestinal Disorders, 2022, 4, 230-236.	0.4	1
231	Estrategias actuales en el diagn \tilde{A}^3 stico y seguimiento de las enfermedades inflamatorias intestinales. Acta Gastroenterologica Latinoamericana, 2022, 52, 306-321.	0.0	0
232	Modern principles of severe ulcerative colitis attack therapy: from simple to complex. Eksperimental naya I Klinicheskaya Gastroenterologiya, 2022, , 268-275.	0.1	0
233	Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy. Gut and Liver, 2023, 17, 49-57.	1.4	2
234	Management of Ulcerative Colitis: Putting Patients at the Centre. European Medical Journal Gastroenterology, 0, , 12-19.	0.0	0
235	Incorporation of Plant-Based Diet Surpasses Current Standards in Therapeutic Outcomes in Inflammatory Bowel Disease. Metabolites, 2023, 13, 332.	1.3	2
236	Predictors of steroid dependence and resistance in patients with ulcerative colitis. Koloproktologia, 2023, 22, 99-107.	0.1	0
237	Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?. Internal Medicine Journal, 2023, 53, 2231-2239.	0.5	2
243	Unresolved challenges in acute severe ulcerative colitis. Indian Journal of Gastroenterology, 2024, 43, 9-14.	0.7	0
244	Predictors of non-response to ongoing conservative therapy in patients with inflammatory bowel disease. , 0, , .		0